Patient‐ and caregiver‐reported impact of symptoms in Duchenne muscular dystrophy
Muscle & Nerve · 2024
DOI: 10.1002/mus.28102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Muscle & Nerve, 2024. Verfasst von Spencer Rosero und 12 weiteren Autor:innen. Beteiligte Einrichtung: University of Rochester Center for Health + Technology (CHeT), Rochester, New York, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Caregivers, Cost of Illness. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Parent Project Muscular Dystrophy, Muscular Dystrophy Association.
Abstract (Originalsprache)
Introduction/Aims To better understand the disease burden faced by individuals with Duchenne muscular dystrophy (DMD) of all ages and elucidate potential targets for therapeutics, this study determined the prevalence and relative importance of symptoms experienced by individuals with DMD and identified factors associated with a higher disease burden.
Methods
We conducted qualitative interviews with individuals with DMD and caregivers of individuals with DMD to identify potential symptoms of importance to those living with DMD. We subsequently performed a cross‐sectional study to assess which symptoms have the highest prevalence and importance in DMD and to determine which factors are associated with a higher disease burden.
Results
Thirty‐nine individuals, aged 11 years and above, provided 3262 quotes regarding the symptomatic burden of DMD. Two hundred participants (87 individuals with DMD and 113 caregivers) participated in a subsequent cross‐sectional study. Individuals with DMD identified limitations with mobility or walking (100%), inability to do activities (98.9%), trouble getting around (97.6%), and leg weakness (97.6%) as the most prevalent and life altering symptomatic themes in DMD. The symptomatic themes with the highest prevalence, as reported by caregivers on behalf of those with DMD for whom they care, were limitations with mobility or walking (90.3%), leg weakness (89.2%), and emotional issues (79.6%). Steroid/glucocorticoid use (e.g., prednisone or deflazacort) was associated with a lower level of disease burden in DMD.
Discussion
There are many symptomatic themes that contribute to disease burden in individuals with DMD. These symptoms are identified by both individuals with DMD and their caregivers and have a variable level of importance and prevalence in the DMD population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Rochester Center for Health + Technology (CHeT), Rochester, New York, USA.
- Princeton University, Princeton, New Jersey, USA.
- Pittsford Sutherland High School, Pittsford, New York, USA.
- Department of Neurology, University of Rochester, Rochester, New York, USA.
ORCID-Profile: Spencer Rosero, Anika Varma
Förderung
- Parent Project Muscular Dystrophy
- Muscular Dystrophy Association
Zitieren
APA
Rosero, S., Weinstein, J., Seabury, J., Varma, A., Dilek, N., Zizzi, C., Coffey, M., Greco, B., Heatwole, J., Alexandrou, D., Guntrum, D., Ciafaloni, E., & Heatwole, C. (2024). Patient‐ and caregiver‐reported impact of symptoms in Duchenne muscular dystrophy. Muscle & Nerve. https://doi.org/10.1002/mus.28102
Vancouver
Rosero S, Weinstein J, Seabury J, Varma A, Dilek N, Zizzi C, et al. Patient‐ and caregiver‐reported impact of symptoms in Duchenne muscular dystrophy. Muscle & Nerve. 2024. doi:10.1002/mus.28102
BibTeX
@article{Rosero2024,
author = {Rosero, Spencer and Weinstein, Jennifer and Seabury, Jamison and Varma, Anika and Dilek, Nuran and Zizzi, Christine and Coffey, Madeleine and Greco, Brittany and Heatwole, John and Alexandrou, Danae and Guntrum, Debra and Ciafaloni, Emma and Heatwole, Chad},
title = {Patient‐ and caregiver‐reported impact of symptoms in Duchenne muscular dystrophy},
journal = {Muscle & Nerve},
year = {2024},
doi = {10.1002/mus.28102}
}
EUVIMED